<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127727">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874275</url>
  </required_header>
  <id_info>
    <org_study_id>VECTTOR DMD2012</org_study_id>
    <nct_id>NCT01874275</nct_id>
  </id_info>
  <brief_title>Duchenne Muscular Dystrophy Clinical Trial</brief_title>
  <acronym>DMD</acronym>
  <official_title>Double-blind, Randomized, Placebo-controlled Study of VECTTOR Treatment for Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alan Neuromedical Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alan Neuromedical Technologies, LLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this investigation is to assess the effectiveness of transcutaneous
      electrical nerve stimulation applied using VECTTOR to reduce the symptoms of Duchenne
      Muscular Dystrophy and reduce the impact of DMD upon the participants' quality of life.

      The primary outcome measures will include:

        1. increased muscle strength and

        2. increased range of joint motions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Increased range of motion</measure>
    <time_frame>measurements aassessed at intervals of 30, 60, 90, 180 and 360 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Range of motion testing (Wireless Tracker System)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increased muscle strength</measure>
    <time_frame>measurement assessed at intervals of 30, 60, 90 180 and 360 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Muscle strength testing (Wireless Tracker system)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>improvement of sleep quality</measure>
    <time_frame>assessed at 90, 180 and 365 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleep Studies will be obtained twice before beginning the study.  The second study will be used as the baseline test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>VECTTOR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>muscle stimulator treatment twice daily for duration of study - 365 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device - sham</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo treatment - no electrical stimulation treatment twice daily for duration of study, 365 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VECTTOR</intervention_name>
    <description>The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.
Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence.</description>
    <arm_group_label>VECTTOR</arm_group_label>
    <arm_group_label>Device - sham</arm_group_label>
    <other_name>electrical muscle stimulator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have Duchenne Muscular Dystrophy diagnosis as confirmed by licensed
             physician, wheelchair bound, &amp; age 15-20 years old.

        Exclusion Criteria:

          -  Active cancer in the area of application of the treatment, infection, skin infection,
             pregnancy, thrombophlebitis, pacemaker, amputation of any part of feet or hands,
             taking steroids.  In addition, the participant may not be in any other clinical trial
             during the time they are in this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Donald Rhodes, MD</last_name>
    <phone>361-992-9432</phone>
    <email>DrRhodes2@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joyce Heinrich</last_name>
    <phone>713-734-4433</phone>
    <email>jheinrich4@comcast.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pediatric Physical Medicine and Rehabilitation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Rhodes, MD</last_name>
      <phone>361-992-9432</phone>
      <email>DrRhodes2@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Joyce Heinrich</last_name>
      <phone>713-734-4433</phone>
      <email>jheinrich4@comcast.net</email>
    </contact_backup>
    <investigator>
      <last_name>Charlotte Stelly-Seitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 10, 2013</lastchanged_date>
  <firstreceived_date>June 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
